RE: Final overall survival: Fulvestrant 500mg vs 250mg in the randomized CONFIRM trial

  1. Martin, M.
  2. Boyer, J.
  3. Stuart, M.
  4. Di Leo, A.
Revue:
Journal of the National Cancer Institute

ISSN: 1460-2105,  0027-8874

Année de publication: 2017

Volumen: 109

Número: 3

Type: Lettre

DOI: 10.1093/JNCI/DJW234 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus